Combined-modality therapy for unresectable, stage III non-small-cell lung cancer--caveat emptor or caveat venditor?
Combined-modality therapy for unresectable, stage III non-small-cell lung cancer--caveat emptor or caveat venditor?
复制标题
不可切除的 III 期非小细胞肺癌的联合疗法——买者自负还是卖方自负？
DOI：
10.1093/jnci/88.17.1175
复制
发表时间：
1996
期刊：
影响因子：
--
通讯作者：
D. Johnson
中科院分区：
文献类型：
--
作者：
D. Johnson
关于这篇文章的评论出现在”Re：不可切除的III期非小细胞肺癌的综合治疗--买者自负还是买者自负？“J Natl Cancer Inst.1996 Dec 18; 88（24）：1866-7.这是对”改善III期非小细胞肺癌生存率：癌症和白血病B组（CALGB）8433试验7年随访“的评论。“J Natl Cancer Inst.1996 Sep 4; 88（17）：1210-5.
A comment on this article appears in" Re: Combined-modality therapy for unresectable, stage III non-small-cell lung cancer--caveat emptor or caveat venditor?" J Natl Cancer Inst. 1996 Dec 18; 88 (24): 1866-7. This is a comment on" Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial." J Natl Cancer Inst. 1996 Sep 4; 88 (17): 1210-5.